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Chemerin is a newly described adipokine with effects on adipocyte differentiation and metabolism
in vitro. Its relationship with body mass index and aspects of the metabolic syndrome suggests a
larger role for this protein in obesity-associated complications.Adipose tissue biology has drawn
much attention over the last several
years, due in part to the increasing in-
cidence of obesity and associated
metabolic disorders and the hope
that understanding the biology of fat
will translate into a cure for bulging
waistlines. Adipose tissue is recog-
nized as an organ that not only stores
energy but also acts as a multifunc-
tional endocrine tissue. Adipocytes
produce hormones (termed adipo-
kines) that regulate systemic pro-
cesses, including food intake and nu-
trient metabolism, insulin sensitivity,
stress responses, reproduction, bone
growth, and inflammation. A growing
number of reports describe proteins
that are secreted from adipocytes
or preadipocytes. While leptin has
systemic effects on appetite and me-
tabolism and is undoubtedly the most
studied secreted adipocyte protein,
endocrine functions have been de-
scribed formultipleadipokines. Inaddi-
tion, autocrine/paracrine factors from
adipocytes influence adipose develop-
ment and metabolism, vascularization,
and recruitment of inflammatory cells.
Two recent publications now add
chemerin (aka RARRES2 or TIG2;
Bozaoglu et al., 2007; Goralski et al.,
2007) to the growing list of secreted
adipocyte proteins. The data indicatethat chemerin has local effects on
adipogenesis and perhaps wider ef-
fects on metabolism and inflammation
(Figure 1).
Chemerin is a secreted chemoat-
tractant protein of 16 kDa, synthe-
sized as prochemerin and activated
through serine protease C-terminal
cleavage triggered as part of host
survival defense (i.e., complement,
fibrinolysis, coagulation, and from leu-
kocyte granules) (Wittamer et al.,
2003). Initially purified from biological
fluids associated with inflammation
(ovarian cancer ascites and rheuma-
toid arthritis synovial fluids), high levels
of mRNA in adipose tissue suggest
a role for chemerin in adipocyte biology
(Bozaoglu et al., 2007; Goralski et al.,
2007). Chemerin is expressed at very
low levels in 3T3-L1 preadipocytes,
but expression and secretion increase
dramatically during adipogenesis
in vitro (Bozaoglu et al., 2007; Goralski
et al., 2007). Adipocytes purified from
adipose tissue contain high levels of
chemerin mRNA; however, substantial
expression in stromal vascular cells
suggests that production from nonadi-
pocytes may also be important (Goral-
ski et al., 2007). Chemerin mRNA
expression is not altered in white adi-
pose tissues of genetically obese ob/
ob mice compared to lean controls,Cell Metabolism 6,but it is increased in subcutaneous adi-
pose tissue of fat sand rats (P. obesus,
whichare actually gerbils)with impaired
glucose tolerance. Chemerin is also
elevated in all adipose tissue depots
in diabetic P. obesus relative to eugly-
cemic lean controls (Bozaoglu et al.,
2007). However, there was no change
in expression in the stromal-vascular
fraction with impaired glucose toler-
anceordiabetes. Inhumans, circulating
levels of chemerin correlate with body
mass index, plasma triacylglycerol
concentrations, and blood pressure
but are not altered by the presence of
type 2 diabetes (Bozaoglu et al., 2007);
the clinical significance of these find-
ings are unclear.
Signalingbychemerin ismediatedby
the seven-transmembrane-spanning
G protein-coupled receptor (GPCR),
chemokine like receptor-1 (CMKLR1).
Expression of this receptor had been
demonstrated in circulating plasmacy-
toid dendritic cells and tissue-resident
macrophages. The new work shows
that, like chemerin, CMKLR1 is highly
expressed in adipose tissues, with
slightly higher expression in adipocytes
compared to stromal vascular cells.
While Goralski et al. observed striking
induction of CMKLR1 expression dur-
ing 3T3-L1 adipogenesis, Bozaoglu
et al. observed repression of this geneSeptember 2007 ª2007 Elsevier Inc. 159
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PreviewsFigure 1. A Model for the Action of Chemerin, an Adipokine with Diverse Effects on Differentiation, Inflammatory Recruitment,
and Metabolism
Local production regulates adipogenesis and through its receptor or possibly other receptors canmodulate a variety of functions inmature adipocytes.
Alongwith previously described adipokines, chemerin, through aparacrine effect,may participate in recruitment and activation of inflammatory cells in
adipose tissue. Chemerin circulates at high levels in the serum and may have systemic effects on metabolism, similar to a host of other adipokines.during preadipocyte differentiation.
CMKLR1 is transcribed from two pro-
moters (Martenssonet al., 2005), which
give rise to alternative noncoding first
exons. Goralski et al. measured pro-
moter 1a-specific transcripts, while
Bozaoglu et al. measured expression
of the coding region, shared by both
promoters. Thus, the origin of the dis-
crepant results is not clear.
CMKLR1 shares homology with a
subfamily of chemoattractant recep-
tors including C5L2. Activation of the
latter by acylation-stimulating protein
results in triacylglycerol synthesis by in-
creasing esterification of fatty acids
with glycerol phosphate. CMKLR1 and
C5L2 are associated with various sig-
naling events including calcium influx
and transient phosphorylation of ERKs
(Maslowska et al., 2006; Wittamer
et al., 2003). CMKLR1maybeactivated
by other ligands, including a fatty-acid
derivative resolvinE1,whichpossesses
anti-inflammatory actions (Arita et al.,
2007). Another fatty-acid-activated
GPCR (i.e., GPR120) is also induced
during differentiation and is required
for adipogenesis (Gotoh et al., 2007).160 Cell Metabolism 6, September 2007These data support a role for multiple
GPCRs in adipocyte biology.
The initial characterization of chem-
erin and CMKLR1 pointed to chemoat-
tractant functions, which may indeed
be involved in the obesity-associated
increase in macrophage infiltration of
adipose tissue (Goralski et al., 2007).
However, experiments reported by
Goralski et al. have expanded the
potential roles for these proteins to
include modulation of adipocyte dif-
ferentiation and metabolism. Knock-
down of either chemerin or CMKLR1
during the early stages of 3T3-L1
adipogenesis resulted in a partial in-
hibition of adipocyte differentiation,
as evidenced by decreased lipid accu-
mulation and reduced expression of
adipocyte markers such as PPARg,
adiponectin, perilipin, and GLUT4.
Knockdown was accompanied by an
increase in expression of IL6 with
a trend toward increased expression
of TNFa. Further, knockdown of chem-
erin resulted in decreased expression
of CMKLR1, and vice versa, suggest-
ing that endogenous signaling through
this pathway maintains their expres-ª2007 Elsevier Inc.sion through a positive feedback
loop. Thus, it is somewhat surprising
that knockdown of chemerin and
CMKLR1 did not completely pheno-
copy each other. While chemerin or
CMKLR1 knockdown partially inhibit
adipogenesis, decreased CMKLR1
expression also results in a few large
adipocytes with uncharacteristic peri-
nuclear lipid accumulation (Goralski
et al., 2007).
Further complicating our under-
standing of the role of chemerin in ad-
ipocyte biology are the data obtained
from mature adipocytes. Knockdown
of chemerin or CMKLR1 in adipocytes
does not cause dedifferentiation as
assessed by lipid accumulation, or
expression of PPARg and adiponectin
(Goralski et al., 2007). The positive
feedback loop between chemerin
and CMKLR1 is not operative in differ-
entiated 3T3-L1 cells, as knockdown
of either mRNA does not influence
expression of the other. However,
chemerin appears to be required for
expression of a subset of adipocyte
genes because knockdown decreases
expression of perilipin, GLUT4,
Cell Metabolism
Previewsadiponectin, and leptin mRNAs. Al-
though not explained by the analyses
performed, chemerin has complex ef-
fects on lipolysis in that knockdown
of chemerin decreases basal glycerol
release, while addition of purified
recombinant chemerin inhibits lipoly-
sis in response to a b-agonist. While
decreased lipolysis is consistent with
effects of chemerin to lower intra-
cellular cAMP (Wittamer et al., 2003),
what is surprising is that knockdown
of CMKLR1 does not block the effects
on lipolysis of purified chemerin
(Goralski et al., 2007). Nor does it
cause the changes in adipocyte gene
expression observed with knockdown
of chemerin. Together with the obser-
vation that knockdown of CMKLR1
does not completely phenocopy the
loss of ligand during adipogenesis,
these data suggest alternate chem-
erin receptors or ‘‘spare receptors’’
such that decreasing expression of
CMKLR1 by 80% is not sufficient to
inhibit chemerin signaling (Goralski
et al., 2007). Assessment of other
downstream signals, such as Erk acti-
vation or cAMP generation, will be
helpful in defining the potential for ad-
ditional receptor subtypes. The finding
by Bozaoglu et al. of a marked reduc-
tion in CMKLR1 in 3T3-L1 adipocytes
does not preclude autocrine and para-
crine effects of chemerin on mature
adipocytes.
New adipokines with diverse biolog-
ical effects are now identified on a reg-ular basis (e.g., lipocalin 2; Yan et al.,
2007). How do the proposed biological
actions of chemerin fit in with the rest
of the adipokine family? Chemerin dis-
ruption has some effect on adipogen-
esis in vitro, but regulation of gene
expression and lipolysis in mature ad-
ipocytes suggests a wider role in lipid
and carbohydrate metabolism, and
perhaps insulin sensitivity (Figure 1).
However, consistent with the finding
that chemerin containing conditioned
media from adipocytes increases
migration of CMLKR1-expressing lym-
phocytes (Goralski et al., 2007) and
increased circulation of chemerin with
obesity (Bozaoglu et al., 2007), the pri-
mary role of chemerin may be in the in-
flammatory response associated with
metabolic stress. Further functional
analysis awaits an understanding of
how chemerin is regulated in vivo, not
only in adipose tissue, but in other tis-
sues that are central to metabolic ho-
meostasis, such as liver. Development
of models with tissue-specific gain or
loss of function for chemerin and/or
CMKLR1 will provide additional insight
into chemerin biology. However, even
these results will require cautious in-
terpretation, as it is clear that no single
adipokine is the answer for how fat
cells cause complications associated
with obesity, including insulin resis-
tance. Indeed, the multitude of adipo-
kines and their overlapping biological
effects suggests that it is the integra-
tion of their actions, in the context ofCell Metabolism 6, Sother genetic and environmental fac-
tors, that will determine weight and
associated health. In the end, con-
quering bulging bellies and chronic
complications will require attacks on
multiple pathways.
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